研究提示称,肥胖性药物的西甘酸盐可能会减少酒精消费,但需要开展更多的研究。 Study hints obesity drug semaglutide may cut alcohol consumption, but larger studies needed.

新的政府资助的研究表明,用于治疗肥胖症的药物,如Ozempic和Wegovy的酸盐,也可能有助于减少酒精消费。 New government-funded research suggests that medications used to treat obesity, such as semaglutide in Ozempic and Wegovy, may also help reduce alcohol consumption. 在这项研究中,将近40%的接受硫酸盐的参与者报告说没有饮酒时间过重,而在安慰剂上,这一比例为20%,大约消费了一半的酒精。 In the study, nearly 40% of participants receiving semaglutide reported no heavy drinking days, compared to 20% on a placebo, and consumed about half the alcohol. 虽然结果大有希望,但专家们强调,需要进行更大规模的研究,以确认调查结果,并评估这些药物对不寻求减肥者的安全性。 While the results are promising, experts emphasize the need for larger studies to confirm the findings and assess the safety of these drugs for those not seeking weight loss.